GLP-1(2836) is a small peptide that targets novel molecular (MTP and sAC) and cellular (caSMC and caEC) mechanisms in myocardial ischemic injury
The Food and Drug Administration (FDA) recently approved semaglutide, also marketed under the name Wegovy, as a common drug
They lower blood glucose levels, slow gastric emptying, lower serum cholesterol and triglyceride levels, reduce liver fat content, decrease the highly inflammatory visceral fat, enhance microvascular (!) blood flows in the muscle tissue, reduce muscle-produced inflammation, microglial activation (neuroinflammation), and enhance neuroplasticity
It is often used alongside ACE inhibitors and ARBs
2023: Lawsuits are filed against Novo Nordisk on behalf of patients who took the drugs and developed gastroparesis/stomach paralysis problems Pop Culture Weight Loss Phenomenon Is Paralyzing Peoples Stomachs FDA, Scientific Studies and Literature on Ozempic, Wegovy, and Rybelsus Gastroparesis/Stomach Paralysis The below studies constitute a small sampling of the scientific literature and studies published on the diabetes weight-loss drugs and gastroparesis/stomach paralysis: Jensterle et al (2023) : Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity This was a small clinical trial of 20 obese female patients with polycystic ovary syndrome who were given semaglutide or placebo
